Context Therapeutics
CNTX
23 hedge funds and large institutions have $3.89M invested in Context Therapeutics in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 2 closing their positions.
600% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 1
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
9% more capital invested
Capital invested by funds: $3.58M → $3.89M (+$311K)
5% more funds holding
Funds holding: 22 → 23 (+1)
2.13% more ownership
Funds ownership: 14.02% → 16.15% (+2.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$260K |
| 2 |
ABG
Ally Bridge Group
New York
|
+$82.1K |
| 3 |
AAA
Affinity Asset Advisors
New York
|
+$69.3K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$21.3K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$15K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$42.9K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$11.3K |
CNTX Hedge Fund Activity: Q3 2023 in Review
23 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Context Therapeutics (CNTX) for Q3 2023, worth a combined $3.89M — up 8.7% from $3.58M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new CNTX positions and 2 closed out — a net gain of 1 holder — while 7 added to existing stakes and 1 trimmed.
The largest buyer was UBS O'Connor, adding an estimated $260K. The largest seller was Two Sigma Investments, exiting entirely with an estimated $42.9K sold.
- 23 institutional investors held Context Therapeutics (CNTX) as of Q3 2023, up from 22 in Q2 2023.
- Funds reported $3.89M of Context Therapeutics stock for Q3 2023, up 8.7% quarter-over-quarter.
- 3 funds opened new Context Therapeutics positions in Q3 2023 and 2 closed out, a net change of +1 holder.
- The largest Context Therapeutics buyer in Q3 2023 was UBS O'Connor, an estimated $260K added.
- The largest Context Therapeutics seller in Q3 2023 was Two Sigma Investments, an estimated $42.9K sold.
Based on aggregated 13F filings for Q3 2023.